Brown Jenifer M, Honzel Brooke, Tsai Laura C, Milks Julia, Neibuhr Yvonne M, Newman Andrew J, Cherney Michael, Stouffer David G, Auchus Richard J, Vaidya Anand
Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension (J.M.B., B.H., L.C.T., J.M., Y.M.N., A.J.N., A.V.).
Division of Cardiovascular Medicine (J.M.B.).
Hypertension. 2025 Feb;82(2):306-318. doi: 10.1161/HYPERTENSIONAHA.124.24153. Epub 2024 Dec 11.
Renin-independent aldosterone production in normotensive people increases risk for developing hypertension. In parallel, normotensive adrenal glands frequently harbor aldosterone-producing micronodules with pathogenic somatic mutations known to induce primary aldosteronism (PA). A deeper understanding of these phenomena would inform the origins of PA and its role in hypertension pathogenesis.
Prospectively recruited normotensives underwent detailed characterization of PA features via the following: oral sodium suppression test to evaluate renin-independent aldosterone production, dexamethasone suppression and adrenocorticotropic hormone-stimulation tests to evaluate adrenocorticotropic hormone-mediated aldosterone production, and 24-hour ambulatory blood pressure monitoring. The magnitude of renin-independent aldosterone production was defined via tertiles of 24-hour urinary aldosterone production during the oral sodium suppression test to create unbiased categorizations of the magnitude of PA. Serum aldosterone, serum 18-hybrid steroids, urine tetrahydroaldosterone (biomarkers of aldosterone synthase activity), urinary potassium, and blood pressure (biomarkers of mineralocorticoid receptor activation) were evaluated across tertiles.
There was a spectrum of autonomous, nonsuppressible, and renin-independent production of aldosterone, 18-hybrid steroids, and 24-hour urinary tetrahydroaldosterone (-trend <0.01). Correspondingly, there was a continuum of adrenocorticotropic hormone-mediated aldosterone production and 18-hybrid steroid production that also paralleled renin-independent aldosterone production. The spectrum of PA pathophysiology was associated with higher ambulatory daytime systolic BP (-trend <0.05), even within the normotensive range, and greater urinary potassium excretion (-trend <0.05), indicating a continuum of mineralocorticoid receptor activation.
The pathophysiologic continuum of PA, characterized by renin-independent and adrenocorticotropic hormone-mediated aldosterone production, and enhanced aldosterone synthase and mineralocorticoid receptor activity, is evident in normotensive people. These findings provide mechanistic explanations to implicate PA in the pathogenesis of a substantial proportion of hypertension.
血压正常人群中不依赖肾素的醛固酮生成会增加患高血压的风险。与此同时,血压正常者的肾上腺经常存在产生醛固酮的微小结节,这些结节带有已知可诱发原发性醛固酮增多症(PA)的致病性体细胞突变。对这些现象的更深入了解将有助于揭示PA的起源及其在高血压发病机制中的作用。
对前瞻性招募的血压正常者通过以下方式进行PA特征的详细表征:口服钠抑制试验以评估不依赖肾素的醛固酮生成,地塞米松抑制试验和促肾上腺皮质激素刺激试验以评估促肾上腺皮质激素介导的醛固酮生成,以及24小时动态血压监测。通过口服钠抑制试验期间24小时尿醛固酮生成的三分位数来定义不依赖肾素的醛固酮生成量,以对PA的程度进行无偏分类。在三分位数中评估血清醛固酮、血清18-混合类固醇、尿四氢醛固酮(醛固酮合酶活性的生物标志物)、尿钾和血压(盐皮质激素受体激活的生物标志物)。
存在醛固酮、1十八-混合类固醇和24小时尿四氢醛固酮的自主性、不可抑制性和不依赖肾素的生成谱(趋势<0.01)。相应地,存在促肾上腺皮质激素介导的醛固酮生成和18-混合类固醇生成的连续谱,其也与不依赖肾素的醛固酮生成平行。PA病理生理学谱与更高的日间动态收缩压相关(趋势<0.05),即使在血压正常范围内也是如此,并且尿钾排泄量更大(趋势<0.05),表明盐皮质激素受体激活的连续性。
以不依赖肾素和促肾上腺皮质激素介导的醛固酮生成以及醛固酮合酶和盐皮质激素受体活性增强为特征的PA病理生理连续谱在血压正常者中很明显。这些发现为PA在很大一部分高血压发病机制中的作用提供了机制解释。